Myosin binding protein C, a phosphorylation-dependent force regulator in muscle that controls the attachment of myosin heads by its interaction with myosin S2

G Kunst, KR Kress, M Gruen, D Uttenweiler… - Circulation …, 2000 - Am Heart Assoc
G Kunst, KR Kress, M Gruen, D Uttenweiler, M Gautel, RHA Fink
Circulation research, 2000Am Heart Assoc
Myosin binding protein C (MyBP-C) is one of the major sarcomeric proteins involved in the
pathophysiology of familial hypertrophic cardiomyopathy (FHC). The cardiac isoform is tris-
phosphorylated by cAMP-dependent protein kinase (cAPK) on β-adrenergic stimulation at a
conserved N-terminal domain (MyBP-C motif), suggesting a role in regulating positive
inotropy mediated by cAPK. Recent data show that the MyBP-C motif binds to a conserved
segment of sarcomeric myosin S2 in a phosphorylation-regulated way. Given that most …
Abstract
—Myosin binding protein C (MyBP-C) is one of the major sarcomeric proteins involved in the pathophysiology of familial hypertrophic cardiomyopathy (FHC). The cardiac isoform is tris-phosphorylated by cAMP-dependent protein kinase (cAPK) on β-adrenergic stimulation at a conserved N-terminal domain (MyBP-C motif), suggesting a role in regulating positive inotropy mediated by cAPK. Recent data show that the MyBP-C motif binds to a conserved segment of sarcomeric myosin S2 in a phosphorylation-regulated way. Given that most MyBP-C mutations that cause FHC are predicted to result in N-terminal fragments of the protein, we investigated the specific effects of the MyBP-C motif on contractility and its modulation by cAPK phosphorylation. The diffusion of proteins into skinned fibers allows the investigation of effects of defined molecular regions of MyBP-C, because the endogenous MyBP-C is associated with few myosin heads. Furthermore, the effect of phosphorylation of cardiac MyBP-C can be studied in a defined unphosphorylated background in skeletal muscle fibers only. Triton skinned fibers were tested for maximal isometric force, Ca2+/force relation, rigor force, and stiffness in the absence and presence of the recombinant cardiac MyBP-C motif. The presence of unphosphorylated MyBP-C motif resulted in a significant (1) depression of Ca2+-activated maximal force with no effect on dynamic stiffness, (2) increase of the Ca2+ sensitivity of active force (leftward shift of the Ca2+/force relation), (3) increase of maximal rigor force, and (4) an acceleration of rigor force and rigor stiffness development. Tris-phosphorylation of the MyBP-C motif by cAPK abolished these effects. This is the first demonstration that the S2 binding domain of MyBP-C is a modulator of contractility. The anchorage of the MyBP-C motif to the myosin filament is not needed for the observed effects, arguing that the mechanism of MyBP-C regulation is at least partly independent of a “tether,” in agreement with a modulation of the head-tail mobility. Soluble fragments occurring in FHC, lacking the spatial specificity, might therefore lead to altered contraction regulation without affecting sarcomere structure directly.
Am Heart Assoc